Evaluation of Ultrasound-guided Transuterine Vaginal Biopsy Technique in Uterine Fibromatous Disease
Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Aug 27, 2024
Trial Information
Current as of August 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new, less invasive way to diagnose uterine tumors, specifically fibroids, in women aged 18 and older. The researchers want to see how effective this ultrasound-guided biopsy technique is, as well as any potential complications that might arise from it. Women who are scheduled for surgery to remove fibroids or their uterus will be invited to participate in the study. Before the biopsy, they'll have a pelvic MRI to help assess their condition.
To join the study, women must be over 18 years old, able to give written consent, and have a valid social security plan. Women who are pregnant, nursing, or have certain medical or legal restrictions cannot participate. The study will include 250 women over about 36 months, with each participant's involvement lasting around 7 months. This trial is important because it could improve how doctors diagnose uterine tumors while minimizing risks for patients.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients over 18 years of age consulting at the hospital who require surgical management for uterine smooth muscle tumors (fibroma or TMM).
- • 2. Able to give written consent
- • 3. Beneficiary or beneficiary of a social security scheme
- Exclusion Criteria:
- • 1. Person in a period of exclusion from another research protocol at the time consent is signed.
- 2. Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code, i.e. :
- • Pregnant women, parturients and nursing mothers
- • Persons deprived of their liberty by judicial or administrative decision
- • Persons subject to psychiatric monitoring under articles L3112-1 and L3113-1 who are not covered by the provisions of article L1121-8.
- • Minors
- • Adults subject to a legal protection measure or unable to express their consent.
- • 3. A person who does not have a sufficient command of the French language to be able to give consent to participate in research.
- • 4. Any other reason which, in the opinion of the investigator, could compromise the safety of the research participant and/or interfere with the evaluation of the research objectives.
About Assistance Publique Hopitaux De Marseille
Assistance Publique - Hôpitaux de Marseille (AP-HM) is a leading public healthcare institution in France, dedicated to providing high-quality medical care and advancing research in various clinical fields. As a prominent sponsor of clinical trials, AP-HM is committed to fostering innovation and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary approach, the institution collaborates with a network of healthcare professionals, researchers, and academic partners to facilitate cutting-edge studies that address critical health challenges. AP-HM's dedication to ethical standards and patient safety underscores its role as a trusted leader in clinical research and healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Laura MIQUEL, Dr
Principal Investigator
Assistance Publique - Hôpitaux de marseille
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported